WuXi XDC Cayman Inc (2268.HK) Q4 2025 Earnings Report

WuXi XDC Cayman Inc delivered a standout QQ4 2025 performance, with revenue of 3,189,264,865 CNY, up 91.5% year over year and 18.1% quarter over quarter. The strong top line flowed through to gross profit of 1,144,655,040 CNY and operating income of 839,524,089 CNY, yielding an operating margin of 26.32% and a net margin of 22.66%. EBITDA stood at 926,972,384 CNY (EBITDA margin of 29.07%), underscoring meaningful operating leverage as volume accelerates in contract development and manufacturing for antibody drug conjugates (ADCs) and related bioconjugates. Net income reached 722,535,985 CNY, with diluted and reported earnings per share of 0.54 and 0.58 respectively, reflecting a solid profitability profile for a high-growth CRO/CMO platform.

The balance sheet exhibits substantial liquidity and a favorable leverage profile: total assets of 14.44B CNY against total liabilities of 3.71B CNY, and stockholders’ equity of 10.73B CNY. Cash and cash equivalents plus short‑term investments total 7.47B CNY, and the company reports a net debt position of -632.0M CNY (net cash), indicating capacity to fund ongoing R&D, capacity expansion, and potential strategic acquisitions without near-term funding pressure. Management commentary and the quarterly cadence suggest continued strength in ADC bioconjugation and discovery-to-manufacturing services, with favorable pricing and utilization dynamics driving margin expansion.

Overall, QQ4 2025 reinforces WuXi XDC Cayman’s position as a high-growth, cash-rich CRO/CMO player within the healthcare diagnostics/biopharma ecosystem. The key near-term questions center on cadence of additional contract wins, utilization of expanded capacity, and retention of North American and European client activity, as the company scales its platform to sustain elevated revenue growth and margin discipline.